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Abstract
The myocyte enhancer factor 2 (MEF2) regulates transcription in
cardiac myocytes and adverse remodeling of adult hearts. Activa-
tors of G protein-coupled receptors (GPCRs) have been reported to
activate MEF2, but a comprehensive analysis of GPCR activators
that regulate MEF2 has to our knowledge not been performed.
Here, we tested several GPCR agonists regarding their ability to
activate a MEF2 reporter in neonatal rat ventricular myocytes. The
inflammatory mediator prostaglandin E2 (PGE2) strongly activated
MEF2. Using pharmacological and protein-based inhibitors, we
demonstrated that PGE2 regulates MEF2 via the EP3 receptor, the
bc subunit of Gi/o protein and two concomitantly activated down-
stream pathways. The first consists of Tiam1, Rac1, and its effector
p21-activated kinase 2, the second of protein kinase D. Both path-
ways converge on and inactivate histone deacetylase 5 (HDAC5)
and thereby de-repress MEF2. In vivo, endotoxemia in MEF2-
reporter mice induced upregulation of PGE2 and MEF2 activation.
Our findings provide an unexpected new link between inflamma-
tion and cardiac remodeling by de-repression of MEF2 through
HDAC5 inactivation, which has potential implications for new
strategies to treat inflammatory cardiomyopathies.
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Introduction
Evidence has been provided that sustained stimulation of receptors
on the plasma membrane of cardiac myocytes by distinct mediators
including endothelin-1 or a-adrenergic agonists is able to trigger the
development of pathological structural changes along with alter-
ations of cardiac gene expression (Backs & Olson, 2006a). A pathog-
nomonic change is the reactivation of the dormant embryonic
isoforms of genes regulating cardiac growth, myocardial contractil-
ity and Ca2+-handling (Backs & Olson, 2006a). In particular, the
reactivation of fetal cardiac gene programs is suggested to lead to
the progression of cardiac remodeling and heart failure. As those
mediators play crucial roles in the activation of fetal gene programs,
it seems a promising approach to identify and describe the distinct
upstream signaling pathways, which may reveal new targets for
therapeutic interventions.
The myocyte enhancer factor 2 (MEF2) transcription factors belong
to the family of MADS (MCM1, agamous, deficiens, SRF) proteins
(Potthoff & Olson, 2007). In mammals, four different MEF2 proteins
exist, named MEF2A, B, C, and D. They bind a common DNA
sequence and drive the expression of specific target genes (Potthoff &
Olson, 2007). The MEF2 proteins have a crucial role in the proper
cardiac development. Due to severe cardiac abnormalities, MEF2A-
and MEF2C-null mice exhibit pre- and perinatal lethality, respectively
(Lin et al, 1997; Naya et al, 2002). In addition to their critical role in
the embryonic development, the MEF2 isoforms and their splicing
variants also govern the stress response in the adult heart by reactiva-
tion of fetal cardiac gene programs (van Oort et al, 2006; Kim et al,
2008; Gao et al, 2016). Whereas MEF2 transgenic mice develop
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ventricular dilation and contractile dysfunction, mice lacking the
MEF2D gene are protected against fetal gene activation, fibrosis, and
cardiac hypertrophy (van Oort et al, 2006; Kim et al, 2008). There-
fore, the activity of MEF2 is tightly controlled. Whereas phosphoryla-
tion by mitogen-activated protein (MAP) kinases and acetylation by
the histone acetyltransferase p300 enhance the transcriptional activity
of MEF2 (Potthoff & Olson, 2007; Wales et al, 2014; Wei et al, 2017),
class IIa histone deacetylases (HDACs; HDACs 4, 5, 7, and 9) physi-
cally interact with MEF2 and recruit other repressive epigenetic
factors (Backs & Olson, 2006a; Lehmann et al, 2014). A protective role
of class IIa HDACs in heart failure has been suggested. For example,
HDAC5 and HDAC9 prevent cardiac hypertrophy (Zhang et al, 2002;
Chang et al, 2004) and HDAC4 is required for the maintenance of
cardiac function during physiological exercise (Lehmann et al, 2018).
Class IIa HDACs can be phosphorylated by several kinases, including
the Ca2+/Calmodulin-dependent protein kinase II (CaMKII), protein
kinase D (PKD), or G protein-coupled receptor kinase 5 (Backs &
Olson, 2006a; Kreusser et al, 2014; Lehmann et al, 2014; Weeks &
Avkiran, 2015). In turn, phosphorylated HDACs are guided by 14-3-3
chaperones from the nucleus to the cytoplasm and MEF2 is released
from the inhibition and can activate downstream genes (Backs &
Olson, 2006a). On the other hand, there are pathways which protect
from the harmful hyper-activation of MEF2 (Lehmann et al, 2014).
For instance, activation of protein kinase A (PKA) has been shown to
inhibit MEF2 activity and moreover to counteract CaMKII-mediated
activation of MEF2 (Backs et al, 2011; Weeks et al, 2017; Lehmann
et al, 2018).
The upstream activation signal of the HDAC-MEF2 axis often
originates from G protein-coupled receptors (GPCRs). The divergent
pathways resulting from GPCRs could have antagonistic effects on
MEF2 activation; therefore, it is difficult to predict the net effect on
MEF2 activation by different mediators. The aim of this study was
to identify new mediators that signal via GPCRs in cardiac myocytes
and which were not known to activate the HDAC-MEF2 axis before.
Furthermore, we sought to explore the detailed resulting down-
stream signaling pathway. We found that prostaglandin E2 (PGE2),
which is one of the main inflammatory mediators, strongly activates
MEF2. PGE2 binds to the Gi/o-coupled EP3 receptor, which activates
divergent, parallel operating signaling pathways; one involving
Tiam1-, Rac1-, and p21-activated kinases (PAK) and another involv-
ing PKD and HDAC5. We found that full MEF2 activation depends
on participation of both pathways and that MEF2 is activated in vivo
in inflamed hearts.
Results
PGE2 activates MEF2 through the EP3 receptor
To identify unknown GPCR-dependent signaling pathways that regu-
late MEF2 activity, we conducted a screening experiment using
neonatal rat ventricular myocytes (NRVMs). NRVMs were infected
with an adenovirus harboring a MEF2-reporter (3xMEF2-Luc), which
responds to endogenous MEF2. Thereafter, the cells were stimulated
with different GPCR agonists for 24 h in serum-free medium. Similar
to previous reports, endothelin-1 (100 nM) activated MEF2 to a high
extent (Backs et al, 2011). On the other hand, the b-adrenergic recep-
tor agonist isoproterenol (1 lM) significantly decreased the basal
level of MEF2 activity. We identified several mediators, which
slightly elevated the activity of MEF2, such as sphingosine-1-phos-
phate (1 lM) or lysophosphatidic acid (10 lM). Strikingly, we
observed a 20-fold activation by two related compounds, namely
prostaglandin E1 (PGE1; 10 lM) and prostaglandin E2 (PGE2; 10 lM;
Fig 1A). In contrast, analogs of other prostaglandins (fluprostenol
and treprostinil, agonists of prostaglandin F and prostacyclin recep-
tors, respectively) had no significant effect. In the following experi-
ments, we focused on PGE2 because of its higher abundance in the
heart in vivo (Herman et al, 1987). The PGE2 effect on MEF2 activity
was concentration-dependent (Fig EV1A). In good agreement with
the ability to activate MEF2, PGE2 triggered the expression of known
specific MEF2 target genes (Potthoff & Olson, 2007; Lehmann et al,
2018), such as Nur77, Myomaxin, or Adamts1 (Fig 1B). MEF2 activa-
tion is commonly associated with the induction of hypertrophic gene
programs. Likewise, PGE2 increased the mRNA levels of the hypertro-
phy marker BNP (Fig 1B) and induced cellular hypertrophy of
NRVMs, which correlated with the induction of MEF2 activity
(Fig 1C). In addition, we observed a similar extent of protein synthe-
sis induction after PGE2 stimulation as with the well-known hyper-
trophic a-adrenoceptor agonist phenylephrine (Fig EV1B). Next, we
aimed to determine the receptor involved in PGE2-mediated MEF2
activation. The four different isoforms of PGE2 receptors (EP1, EP2,
EP3, EP4) show a different degree of G protein coupling and expres-
sion patterns (Woodward et al, 2011). Each of the four types is
expressed in cardiac myocytes, but EP3 and EP4 receptors are the
most abundant isoforms (Di Benedetto et al, 2008). The EP3 receptor
antagonist L798106 inhibited PGE2-dependent MEF2 activation
(Figs 1D and EV1C), while neither the EP4 receptor antagonist L-
161,982 (2 lM) nor the EP1/EP2 receptor antagonist AH6809 (10 lM)
led to an alteration of MEF2 activity, suggesting the EP3 receptor as
the underlying receptor to activate MEF2 by PGE2 in NRVMs.
PGE2 activates MEF2 through Gi/o proteins
The EP3 receptor is generally considered to couple to pertussis toxin
(PTX)-sensitive Gi/o proteins, thereby decreasing intracellular cAMP
levels. In accordance, EP3 receptor inhibition by L798106 increased
the isoproterenol-induced phosphorylation of phospholamban, a
known cAMP-regulated protein (Cuello et al, 2007; Fig EV1D).
However, the EP3 receptor has several splice variants, which differ
in the G protein-coupling properties (Woodward et al, 2011). There-
fore, we examined which heterotrimeric G protein types are essential
for the PGE2-mediated MEF2 activation by a pharmacological and
molecular approach (Fig 2A). Regulator of G protein signaling (RGS)
proteins are GTPase activating proteins (GAPs) and specifically block
different classes of G proteins. RGS16 is a GAP for Gi/o and Gq/11
proteins, RGS2 suppresses Gq/11, while RGS-LSCII inhibits the G12/13
signaling pathway (Vettel et al, 2012). Like RGS2, p63ΔN, a specific
scavenger of activated Gaq/11 proteins did not affect the PGE2-
induced activity of MEF2. In contrast, the Gi/o and Gq/11 inhibitor
RGS16 (Fig 2B), as well as pretreatment with pertussis toxin (PTX,
100 ng/ml) attenuated the PGE2 response (Fig 2C). We did not
observe any significant effect of RGS-LSCII overexpression in this
setting (Fig 2B). These data suggest that neither Gq/11- nor G12/13-,
but the PTX-sensitive Gi/o protein activation is required for the PGE2
response. To rule out an involvement of Gs proteins, we inhibited
adenylyl cyclase, the effector enzyme of Gs proteins. The adenylyl
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Figure 1. Screening the effect of different GPCR agonists on MEF2 activity.
A Neonatal rat ventricular myocytes (NRVMs) were infected with the 3xMEF2-Luc reporter, serum starved for 20 h, and stimulated for 24 h with different agonists:
100 nM endothelin-1 (ET1), 1 lM sphingosine-1-phosphate (S1P), 10 lM lysophosphatidic acid (LPA), 1 lM WIN55,212-2 (WIN55, cannabinoid receptor agonist),
1 lM isoproterenol (ISO, b-adrenergic receptor agonist), 100 nM angiotensin II (AngII), 10 lM prostaglandin E1 (PGE1), 10 lM prostaglandin E2 (PGE2) or 100 nM
prostanoid F receptor agonist fluprostenol (Flupro), 100 nM treprostinil (Trepro, prostacyclin receptor agonist).
B PGE2 induces the expression of MEF2 target genes. NRVMs were serum starved for 24 h, then were stimulated with 1 lM PGE2 for 2 h, and mRNA levels of the
indicated genes were determined.
C Correlation between MEF2 activation and NRVM hypertrophy. MEF2 activity was measured as in (A) upon increasing concentration of PGE2. Cell size of NRVMs was
determined after 48-h stimulation with the indicated concentrations of PGE2. Left: Representative images of a-actinin stained NRVMs stimulated with DMSO, 300 nM
PGE2, or 1 nM ET1. Scale bar is 10 lm.
D PGE2 activates MEF2 via EP3 receptor. NRVMs were infected with the 3xMEF2-Luc reporter and serum starved for 20 h. The cells were stimulated with DMSO or 1 lM
PGE2 for 24 h in the presence or absence of different EP receptor antagonists: AH6809 (10 lM, EP1- and EP2-antagonist) or 798106 (200 nM, EP3-antagonist) or
L161,982 (2 lM, EP4-antagonist).
Data information: Values are mean  s.e.m. In (A), the experiment was performed in triplicates, and similar results were obtained in three different experiments.
Student’s two-tailed t-test, *P < 0.05 vs. control (ET1, P = 0.0013; S1P, P = 0.0144; LPA, P = 0.026; WIN55, P = 0.6205; ISO = 0.0399; AngII, P = 0.5812; PGE1, P = 0.001;
PGE2, P < 0.0001; Flupro, P = 0.0846; Trepro, P = 0.1958). In (B), n = 5, technical replicates, Student’s two-tailed t-test, *P < 0.05 vs. control (Nur77, P = 0.0148;
Myomaxin, P = 0.0417; Adamts1, P = 0.0112; BNP, P = 0.0065). In (C), NRVM cell size was determined from a minimum of 100 cells of three technical replicates upon
different concentrations of PGE2, and MEF2 activity was parallel assessed from six technical replicates. Correlation was statistically analyzed by calculating Pearson
correlation coefficient (Pearson r = 0.9626, P = 0.0021). In (D), n = 3, independent experiments, *represents significant interaction between the two treatments (P < 0.05,
two-way ANOVA, AH6809, P = 0.1092; L798106, P = 0.0002; L161,982, P = 0.5579).
Source data are available online for this figure.
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cyclase inhibitor SQ22536 (100 lM) did not affect MEF2 activity
(Fig 2C). In addition, since the adenylyl cyclase inhibition also
mimics the effect of Gai/o, the absence of alteration suggested
that not the a, but the bc subunit of Gi/o is the transducer in the
PGE2-mediated MEF2 activation. In accordance, overexpression of
Gat to scavenge the free Gbc subunits abolished the PGE2 effect
(Fig 2D). Similar results were obtained with the overexpression of
long isoform of RGS3 (RGS3L), another Gbc scavenger (Vogt et al,
2007; Fig EV2). Taken together, these data indicate that the
PGE2-induced MEF2 activation is mediated by the bc subunit of Gi/o
proteins.
PGE2 induces HDAC5 hyperphosphorylation and de-repression of
MEF2 via PKD
Among critical regulators of MEF2 are class IIa HDACs. A well-
known mechanism of de-repression of MEF2 activity is HDAC phos-
phorylation followed by its concomitant nucleo-cytoplasmic shut-
tling. Therefore, we analyzed the phosphorylation status of HDAC5
by Western blot. We overexpressed FLAG-tagged HDAC5 in
NRVMs. After stimulation with PGE2, we observed a high extent of
hyperphosphorylation of HDAC5 at Ser-498 (Fig 3A), similarly to




Figure 2. PGE2-mediated MEF2 activation is Gi/o-bc dependent.
A Illustration of the target points of the used pharmacological and protein-based inhibitors.
B–D (B, D) NRVMs were infected with the 3xMEF2-Luciferase reporter and with recombinant adenoviruses encoding EGFP (AdGFP), RGS16, RGS2, p63DN, RGS-LSCII, or
Gat, as indicated. The cells were serum starved for 20 h and stimulated with DMSO or 1 lM PGE2 for 24 h. (C) NRVMs were infected with the 3xMEF2-Luciferase
reporter and pretreated with the adenylyl cyclase inhibitor SQ22536 (100 lM) for 20 min or the Gi/o protein inhibitor pertussis toxin (PTX, 100 ng/ml) for 20 h in
serum-starved conditions and treated with DMSO or 1 lM PGE2 for 24 h.
Data information: In (B–D), n = 3, independent experiments, *represents significant interaction between the two treatments (P < 0.05, two-way ANOVA, RGS16,
P < 0.0001; RGS2, P = 0.1725; p63DN, P = 0.0666; RGS-LSCII, P = 0.0818, SQ22536, P = 0.385; PTX, P < 0.0001; Gat, P < 0.0001), values are mean  s.e.m.
Source data are available online for this figure.
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Ser-498 is a specific phosphorylation site of protein kinase D (PKD;
Haworth et al, 2011), we examined whether PKD is responsible for
the phosphorylation of HDAC5. Indeed, pretreatment with the
specific PKD-inhibitor BPKDi (3 lM; Meredith et al, 2010;
Monovich et al, 2010) diminished the PGE2-induced HDAC5 phos-
phorylation. In accordance, phosphorylation of PKD was increased
at Ser-744/Ser-748 and Ser-916 sites upon PGE2 treatment in
NRVMs (Fig 3B), which was partly (phosphorylation at Ser-744/
Ser-748) observed in adult mouse ventricular myocytes as well
(Fig EV3). Different mechanisms of PKD activation exist. It is
known that PKD can be activated in a protein kinase C (PKC)-
dependent way, e.g., by PE. In contrast, ET1 stimulates PKD activity
in a PKC-independent manner in NRVMs (Vega et al, 2004; Harrison
et al, 2006; Haworth et al, 2007; Guo et al, 2011). Thus, the involve-
ment of PKC in the PGE2-mediated PKD and HDAC5 phosphorylation
was examined. Phosphorylation of PKD at Ser-744/Ser-748, a well-
known PKC-target site, was diminished upon pretreatment with the
PKC-inhibitor bisindolylmaleimide I (BIM, 2 lM). However, phos-
phorylation of the autophosphorylation site (Ser-916) was only
slightly decreased (Fig 3B), and HDAC5 phosphorylation at Ser-498
was not altered (Fig 3A) by BIM, suggesting that the activation of
PKD by PGE2 occurs both PKC dependently and PKC independently.
Nevertheless, BPKDi prevented MEF2 activation by PGE2 (Fig 3C). In
contrast, inhibition of another HDAC kinase, CaMKII, by auto-
camtide-2-related inhibitory peptide II (AIP, 1 lM) did not affect




Figure 3. PGE2 induces HDAC5 hyperphosphorylation and concomitant MEF2 activation via PKD.
A, B NRVMs were infected with recombinant adenovirus encoding Flag-HDAC5 (A) or not infected (B) and serum starved for 20 h. The cells were pretreated with the
PKC-inhibitor bisindolylmaleimide I (2 lM) or the PKD-inhibitor BPKDi (3 lM) for 20 min and stimulated with 100 nM endothelin-1 (ET1) or 100 lM
phenylephrine (PE) or 1 lM PGE2 for 4 h, as indicated. HDAC phosphorylation was detected by immunoblotting with the anti-HDAC5 phospho-Ser-498 antibody,
phosphorylation of PKD was assessed using anti-phospho-PKD antibodies (Ser-744/Ser-748 and Ser-916), and representative images are shown from three
independent experiments.
C NRVMs were infected with the 3xMEF2-Luc reporter and serum starved for 20 h. The cells were pretreated with the PKD-inhibitor BPKDi (3 lM) or the CamKII-
inhibitor AIP (1 lM) for 20 min and stimulated with DMSO or 1 lM PGE2 for 24 h. N = 3, *represents significant interaction between the two treatments (P < 0.05,
two-way ANOVA, BPKDi, P < 0.0001; AIP, P = 0.2197). Values are mean  s.e.m. The exact n and P-values can also be found in the Source Data Excel file for Fig 3.
Source data are available online for this figure.
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promotes HDAC5 hyperphosphorylation and de-repression of MEF2
activity via PKD.
PGE2 triggers Rac1 activation via Tiam1
Several effector partners of Gi/o-bc have been described, among
others the small G protein Rac1 and RhoA (Vogt et al, 2007). To test
whether these small G proteins are activated by PGE2 in NRVMs, we
performed effector pull-down assays and we found, that exclusively
Rac1, but not RhoA is activated after PGE2 stimulation (Fig 4A). To
examine whether Rac1 activation is Gi/o-dependent, we used PTX
treatment and overexpression of RGS16. Both manipulations
suppressed the PGE2-induced Rac1 activation (Fig 4B and C). Earlier
studies have shown that the Gi/o-mediated Rac1 activation in NRVM
can occur in a Gi/o-bc-, phosphatidyl-inositol-3-kinase (PI3K)-, and





Figure 4. PGE2 induces Rac1 and MEF2 activation via Gi/o and the RacGEF Tiam1.
A NRVMs were serum starved for 24 h and stimulated for 2 min with 10 lM PGE2. Rac1 and RhoA GTPase activation was determined by effector pull-down assay and
analyzed by immunoblot.
B NRVMs were infected with recombinant adenoviruses encoding EGFP (AdGFP) or RGS16 24 h prior to stimulation, and then, Rac1 activity was measured.
C Cells were pretreated with 100 ng/ml pertussis toxin (PTX, Gi/o-inhibitor) for 24 h or with 50 lM NSC23766 (NSC, Tiam1–Rac1 interaction inhibitor) for 2 h.
Thereafter, Rac1 activation was determined by effector pull-down assay.
D NRVMs were transduced with the 3xMEF2-Luc reporter and were serum starved for 20 h. After 2 h of 50 lM NSC23766 (A) pretreatments, the cells were stimulated
with DMSO or 1 lM PGE2 for 24 h, and then, MEF2 activity was determined. NSC abolished the MEF2 activation by PGE2.
Data information: In (A–C), representative images from at least three independent experiments are shown. In (B–D), values are mean  s.e.m., (B, C) n = 4; (D), n = 3;
*P < 0.05 (two-way ANOVA, RGS16, P = 0.0415 (B); PTX, P = 0.039 (C), NSC effect on Rac1 activation, P = 0.0412 (C); NSC effect on MEF2 induction, P < 0.0001. PGE2
effect was significant in Rac1 activation, P < 0.0001). The exact n and P-values can also be found in the Source Data Excel file for Fig 4.
Source data are available online for this figure.
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and that the interaction between Tiam1 and Rac1 can be inhibited
by NSC23766 (Vettel et al, 2012). Treatment with 50 lM NSC23766
(NSC) diminished the PGE2-induced Rac1 activation (Fig 4C),
suggesting that PGE2 triggers Rac1 activation via Gi/o and Tiam1.
PGE2-induced MEF2 but not PKD activation requires
Tiam1-dependent Rac1 activation
We hypothesized that MEF2 activation by PGE2 may thus occur
downstream of Tiam1 and Rac1. For verification, we treated NRVMs
with NSC (Fig 4D). The Tiam1–Rac1 interaction inhibitor dimin-
ished the MEF2 activation after PGE2 stimulation, indicating that the
PGE2-induced signaling pathway toward MEF2 includes Tiam1 and
Rac1. To investigate the theoretical possibility that Rac1 exerts its
effect on MEF2 through PKD, we measured PKD phosphorylation
after treatment with NSC (Fig 5A). However, PGE2-induced PKD
phosphorylation at Ser-744/Ser-748 and Ser-916 was not affected by
NSC treatment. Likewise, NSC could not prevent PGE2-induced
HDAC5 phosphorylation at Ser-498 (Fig 5B). Moreover, inhibition
of PKD did not block the Rac1 activation (Fig EV4). p21-activated
kinases (PAKs) are well-characterized effector proteins of Rac1
(Vettel et al, 2012). In accordance, the phosphorylation of the isoform
2 of PAK (PAK2) was increased upon PGE2 at Ser-192/Ser-197 and
Thr-402 sites in NRVMs in a partly EP3 receptor-dependent manner
but not in cardiac fibroblasts, similar to the phosphorylation of PKD
(Fig 5C). Thus, we examined their role in MEF2 regulation, as possi-
ble participants in the Rac1-induced MEF2 activator pathway.
Indeed, the PAK inhibitor IPA-3 (30 lM) significantly attenuated the
activation of MEF2 upon stimulation with PGE2 (Fig 5D). We then
tested whether the Tiam1–Rac1–PAK2 pathway regulates the cellu-
lar localization of HDAC5. Like ET1, PGE2 induced the nucleo-cyto-
plasmic shuttling of HDAC5 (Fig 6). Strikingly, IPA-3 decreased the
cytosolic translocation of HDAC5, similar to the PKD-inhibitor
BPKDi, which was even stronger through a combined pretreatment
with both compounds. These findings suggest that PGE2 promotes
more likely two parallel pathways regulating nucleo-cytoplasmic
shuttling of HDAC5. The first is dependent on PKD activation and
HDAC phosphorylation, and the other involves the Tiam1–Rac1-
mediated activation of PAK2 affecting nucleo-cytoplasmic shuttling
of HDAC5 by a mechanism that remains to be identified. Thus, two
pathways converge on HDAC5 and may promote MEF2 activation
synergistically.
Cardiac inflammation leads to increased myocardial PGE2 levels
and MEF2 activation in vivo
To confirm the in vivo relevance of these results, we used the LPS-
induced endotoxemia model to induce myocardial inflammation.
The inflammatory effect in this model was confirmed by increased
mRNA levels of pro-inflammatory cytokines including interleukin 6
(IL6) and tumor necrosis factor a (TNFa; Fig 7A). Importantly, the
LPS-treated mice displayed more than twofold higher levels of PGE2
in the myocardium (Fig 7B). Histological and “whole organ” stain-
ing of b-galactosidase activity in MEF2-lacZ reporter mice showed a
lacZ-positive myocardium and in particular cardiac myocytes as sign
for MEF2 activation in cardiac myocytes, which was not observed in
sham-treated mice (Fig 7C). Moreover, we found increased activity
of the in vitro identified pathways upstream to MEF2 in
inflammation. Phosphorylation of PKD at Ser-744/Ser-748 and of
HDAC5 was significantly elevated, and we observed a slight but
statistically significant increase of PAK2 phosphorylation at Thr-402
(Fig 7D).
Discussion
Our results identify PGE2 as a powerful activator of the MEF2 tran-
scription factor in cardiac myocytes. PGE2 is one of the main media-
tors of inflammation (Woodward et al, 2011). Several studies linked
chronic inflammation with the progression of cardiac remodeling
and heart failure but the exact mechanism how signals are trans-
duced toward cardiac gene expression are not understood (Hofmann
& Frantz, 2013). Since the role of MEF2 is well established in tran-
scriptional activation that drives adverse cardiac remodeling, our
findings reveal a yet unrecognized link between myocardial
inflammation and adverse remodeling leading to heart failure and
unmask potential new drug targets in the setting of inflammatory
cardiomyopathies. Accordingly, several groups have shown that
PGE2 induces cardiomyocyte hypertrophy but could not link their
results to a distinct transcriptional pathway (Mendez & LaPointe,
2005; Frias et al, 2007; He et al, 2010). In these studies, pro-hyper-
trophic effects of the Gi/o-coupled EP3 and the Gs-coupled EP4 recep-
tors were reported. Here, we show that the EP3, but not EP4
receptor is responsible for the induction of MEF2 activity, suggesting
that EP4 signals to another transcriptional pathway that still needs
to be identified.
Phosphorylation of class IIa HDACs is a critical signaling event
for their nucleo-cytoplasmic shuttling and de-repression of MEF2
activity (Vega et al, 2004). Here, we show that PGE2 leads to activa-
tion of PKD and HDAC5 phosphorylation at its 14-3-3 binding site
that induces nucleo-cytoplasmic shuttling. HDAC5 phosphorylation
was not influenced by CaMKII inhibition, which is consistent with
our previous results that CaMKII selectively phosphorylates HDAC4
but not HDAC5 (Backs et al, 2006b, 2008). On the other hand, data
of our group suggested a role of CaMKII for leukocyte recruitment
via a newly identified cardiac myocyte-intrinsic immune response
(Weinreuter et al, 2014), suggesting the existence of another
CaMKII-HDAC4-dependent pathway in cardiac inflammation that is
independent of the here described PGE2-EP3-PKD-HDAC5 axis.
Protein kinase D is considered as a powerful mediator of myocar-
dial contraction, cardiac hypertrophy, and remodeling (Cuello et al,
2007; Avkiran et al, 2008; Fielitz et al, 2008). Interestingly, the
properties of PKD activation originating from different GPCRs can
show distinct characteristics in cardiac myocytes. For example, the
a1-adrenergic receptor agonist phenylephrine only activates PKD in
a PKC-dependent manner and the activated form rapidly shuttles
from the sarcolemma to the nucleus. In contrast, ET1 can activate
PKD via PKC-dependent and PKC-independent signaling pathways
and promotes more sustained activation of PKD at the sarcolemma
(Bossuyt et al, 2011). We found that PGE2, like ET1, can activate
PKD also through a PKC-independent mechanism. Thus, we propose
that PGE2 stimulates PKD via Gi/o-bc. Gbc was demonstrated to acti-
vate PKD directly by interaction with its pleckstrin homology
domain (Jamora et al, 1999). In addition, Gbc was also shown to
hinder HDAC5 activity through direct binding, which might add to
the effects described in this study (Spiegelberg & Hamm, 2005).
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Monomeric GTPases of the Rho family have been associated with
regulation of HDAC function. For example, activation of RhoA leads to
HDAC5 phosphorylation (Harrison et al, 2006). Gi/o-coupled receptors
are able to activate several RhoGTPases, including RhoA and Rac1 in
cardiac myocytes (Vogt et al, 2007). However, we only could detect
increased Rac1 activity after PGE2 stimulation. Rac1 is apparently indis-
pensable for the hypertrophic response of cardiac myocytes (Pracyk





Figure 5. PGE2 activates MEF2 through PAK2 in NRVMs.
A After serum starvation, NRVMs were pretreated with or without 50 lM NSC23766 for 2 h and stimulated with 1 lM PGE2 for 1 h. Total and phosphorylated PKD
levels were analyzed by immunoblot. PKD was activated by PGE2, but it was not affected by NSC.
B After infection with Flag-HDAC5 and serum starvation, NRVMs were treated with 50 lM NSC23766 for 2 h prior to stimulation. The cells were stimulated with 1 lM
PGE2 for 1 h. HDAC5 phosphorylation at Ser-498 was detected by immunoblot. The phosphorylation of HDAC5 at this site was not prevented by NSC.
C NRVMs and neonatal cardiac fibroblasts (CFs) were serum starved, pretreated with vehicle or 200 nM L798106 (EP3 receptor antagonist) for 20 min, and were
stimulated with 1 lM PGE2 for 10 min. PAK2 and PKD phosphorylation were assessed by immunoblot. Calsequestrin was used as a myocyte marker.
D MEF2 activity was determined in cells infected with the 3xMEF2-Luc reporter after serum starvation. Cells were stimulated with vehicle or 1 lM PGE2 for 24 h after
1-h of 30 lM IPA-3 pretreatment. IPA-3 inhibited the MEF2 activation by PGE2.
Data information: In (A–C), representative images from three independent experiments are shown. In (D), values are mean  s.e.m., n = 3, biological replicates, *P < 0.05
(two-way ANOVA, P < 0.0001). The exact n and P-values can also be found in the Source Data Excel file for Fig 5.
Source data are available online for this figure.
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promotes oxidative stress by activation of NADPH oxidase and contri-
butes to cardiac injury and malfunction (Maack et al, 2003; Ma et al,
2013). Rac1 signaling was also shown to lower class I HDAC activity in
cardiac myocytes (Ma et al, 2013). Earlier, we reported that stimulation
of a1A-adrenergic receptors promotes Rac1 activation, which is required
for myocyte hypertrophy. This Rac1 activation was mediated by Gi/o-
bc/PI3K signaling and by the widely expressed RacGEF Tiam1 (Vettel
et al, 2012). Similarly, we found that the PGE2-mediated Rac1 activa-
tion depends on Tiam1 and the Tiam1–Rac1–PAK pathway was essen-
tial for MEF2 activation. We found that, similar to PKD, PAK2
activation contributes to nucleo-cytoplasmic shuttling of HDAC5 upon
PGE2 stimulation. These findings suggest that simultaneous activation
of at least two different pathways converge on HDAC5 and subse-
quently MEF2. Whether and where PAK2 phosphorylates HDAC5
directly or indirectly remains however to be determined. Thus, we
propose a model, in which PGE2-dependent MEF2 activation requires
nucleo-cytoplasmic shuttling of HDAC5 by PKD and Rac1-PAK2 in
parallel (Fig 8). The necessity of multiple signaling pathways for the
complete activation of MEF2 is in good agreement with the results of
previous studies. For instance, nuclear export of HDACs can be blocked
without altering their phosphorylation, and acetylation of MEF2 was
shown to be essential for its complete activation (Wei et al, 2017). In
earlier studies, PGE2 has also been shown to elevate the intracellular
cAMP level in cardiac myocytes through the EP4 receptor (Liu et al,
2012). We and others have demonstrated before that increased cAMP
levels after b-adrenergic receptor stimulation counteracts MEF2 activa-
tion (Backs et al, 2011; Haworth et al, 2012; Chang et al, 2013;
Lehmann et al, 2014, 2018). Interestingly, PGE2 increases cAMP
concentration in different cellular compartments than b-adrenergic
receptors (Liu et al, 2012). We speculate that the b-adrenergic receptor-
induced cAMP pool may be more efficient to repress MEF2 than the
PGE2-induced pool. Since PKA activation was associated with both
beneficial and deleterious outcomes in cardiac myocytes (Lehmann
et al, 2014), it would be valuable to determine the exact cAMP
compartment responsible for MEF2 repression because its pharmaco-
logical manipulation may offer advantageous impact.
Figure 6. PGE2-induced nuclear export of HDAC5 is regulated by both PKD and PAK2.
Top: GFP-HDAC5-infected NRVMs were serum starved for a day, pretreated for 2 h with the indicated compounds (BPKDi, 3 lM, IPA-3, 30 lM) alone or in combination, then
were stimulated for 4 h. Representative images. Scale bar is 10 lm. Bottom: Statistical analysis of cellular localization of HDAC5. GFP-HDAC5 localization (nuclear or cytosolic)
was assessed in > 100 cells of each sample (n = 3, technical replicates). *P < 0.05 (one-way ANOVA with Bonferroni post hoc test, vehicle vs. ET1 or vs. PGE2, P < 0.0001; PGE2
vs. PGE2 + BPKDi, P = 0.0004; PGE2 vs. PGE2 + BPKDi, P = 0.0114; PGE2 vs. PGE2 + BPKDi + IPA-3, P < 0.0001). The exact n and P-values can also be found in the Source Data
Excel file for Fig 6.
Source data are available online for this figure.
ª 2018 The Authors EMBO Molecular Medicine 10: e8536 | 2018 9 of 16




Figure 7. LPS-induced endotoxemia leads to myocardial inflammation, increased myocardial PGE2 levels, and MEF2 activation.
MEF2-lacZ reporter mice (BALB/c background, 6–12 weeks old) were treated with 7 mg/kg lipopolysaccharide from Escherichia coli (O111:B4) or saline intraperitoneally and
were sacrificed after 24 h.
A mRNA levels of different inflammatory cytokines, as indicated. The graphs show relative mRNA levels, fold increase compared to saline-treated controls, normalized to
18s content.
B PGE2 was quantified after mechanical homogenization of deeply frozen hearts using nano-liquid chromatography-tandem mass spectrometry.
C Histologic and macroscopic stainings of b-galactosidase activity in MEF2-lacZ reporter mice show MEF2 activation (blue cells and precipitates, respectively) in the
myocardium upon LPS treatment. Saline-treated littermates served as control. Scale bar of histological stainings is 100 lm. Quantification of whole-heart stainings is
shown in the right panel (pixel intensity in blue channel normalized to total intensity).
D Induction of PKD, HDAC5, and PAK2 in myocardial inflammations. Immunoblots were performed on extracts of hearts of saline- and LPS-treated mice. Representative
blots are shown in the left panel, and the quantification is in the right panel.
Data information: Values are mean  s.e.m. The exact n values are shown in the bottom of the bar graphs. *P < 0.05, Welch’s two-tailed unpaired t-test was used for
statistical analysis, n.s. = not significant. In (C), representative images of myocardial sections are shown from three independent experiments and representative whole
hearts of six independent experiments. P-values: IL6, P = 0.0007 (A); TNFa, P < 0.0001 (A); PGE2, P = 0.0016 (B); blue pixel intensity, P = 0.0083 (C); phospho-PKD-Ser-
744/Ser-748, P = 0.0049 (D); phospho-PKD-Ser-916, P = 0.2684 (D); phospho-HDAC5-Ser-498 (D), P = 0.0019; phospho-HDAC5-Ser-259, P = 0.0003 (D); phospho-PAK2-
Ser-192/Ser-197, P = 0.1962 (D); phospho-PAK2-Thr-402, P = 0.0446 (D). The exact n and P-values can also be found in the Source Data Excel file for Fig 7.
Source data are available online for this figure.
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Therapeutic implications
Besides the in vitro data, we provide in vivo evidence that cardiac
inflammation in a sepsis model induces activation of MEF2. Thus,
the unmasked upstream signaling pathway consisting of PGE2, EP3,
Rac1, and PKD may provide a number of new drug target candi-
dates for the treatment of heart failure in the specific setting of
inflammatory causes. Cyclooxygenase inhibitors, such as acetylsali-
cylic acid, are generally used as anti-inflammatory, anti-nocicep-
tive, and anti-thrombotic agents (Woodward et al, 2011). However,
these drugs inhibit the synthesis of all prostaglandin types, and
some of them, besides others prostacyclin, were shown to have
beneficial effects in cardiovascular homeostasis (Woodward et al,
2011). A more specific approach could be the inhibition of microso-
mal prostaglandin E synthases (mPGES), the responsible enzymes
for PGE2 production. However, mice lacking mPGES show worse
cardiac function after angiotensin II infusion and develop adverse
cardiac remodeling in an experimental model of myocardial infarc-
tion (Degousee et al, 2008; Harding et al, 2011). Cardiac-specific
EP4
/ mice suffer from reduced cardiac function after MI and
dilated cardiomyopathy develops with aging in EP4
/ male mice
(Qian et al, 2008; Harding et al, 2010). These results indicate that
PGE2 may play an important role in maintaining the cardiac home-
ostasis partly through EP4 signaling. On the other hand, overex-
pression of EP3 receptors induces cardiac hypertrophy in the
murine heart (Meyer-Kirchrath et al, 2009). A role of EP3 receptor
was also demonstrated in the promotion of vascular neointimal
hyperplasia and formation of thrombocyte aggregation (Woodward
et al, 2011; Zhang et al, 2013). In patients with severe heart failure,
PGE2 levels are significantly higher, indicating the hyper-activation
of the prostaglandin system (Dzau et al, 1984). Thus, our findings
imply that EP3 receptors represent a potential target in the treat-
ment of inflammatory cardiomyopathy. Moreover, the identified
downstream molecules of EP3 such as PKD or Rac1/PAK2 could
also represent novel drug targets for inflammatory cardiomy-
opathies, for which no specific therapeutic strategies are available
yet (Heymans et al, 2009; Suthahar et al, 2017). Further in vivo
investigations using, e.g., EP3-, PKD-, or MEF2D-deficient mice in
the context of inflammatory cardiomyopathies are warranted to
determine a critical role of the above mentioned signaling pathways
and may facilitate translational studies toward personalized strate-
gies to combat inflammatory cardiomyopathies.
Materials and Methods
Chemical reagents
Phenylephrine (PE), endothelin-1 (ET1), dibutyryl-cAMP, AH6809,
L-798106, isoproterenol, and bicinchoninic acid protein assay kit
were purchased from Sigma-Aldrich. Prostaglandin E1, prosta-
glandin E2, SQ 22536, and treprostinil were purchased from Santa
Cruz, autocamtide-2-related inhibitory peptide II, L-161,982, bisin-
dolylmaleimide, and pertussis toxin from Calbiochem. Sphingosine-
1-phosphate, lysophosphatidic acid, IPA-3, and NSC23766 were
from Tocris. Fluprostenol was from Cayman, and WIN55,212-2 was
from Enzo. Angiotensin II was bought from American Peptide, and
the Luciferase Assay Kit was purchased from Promega. BPKDi was
custom-synthesized (Haworth et al, 2012). [4,5-3H]-leucine was
from Perkin-Elmer. Cell culture reagents were from Invitrogen.
Cell culture and adenoviral infection
Neonatal rat ventricular myocytes (NRVMs) were isolated from 1-
to 2-day-old Sprague Dawley rats as previously described (Backs
et al, 2006b). After isolation, NRVMs were maintained in DME/199
medium (4:1) with 10% FBS, 2 mM L-glutamine, 100 U/ml peni-
cillin, and 100 lg/ml streptomycin. NRVMs were infected 48 h after
plating, grown 24 h in serum-free media. Adenoviruses (Ad)
harboring FLAG-HDAC4, FLAG-HDAC5, 3xMEF2-Luc, GFP, RGS2,
RGS16, p63DN, RGS-LSCII, RGS3L, and transducin a were described
before and used with 10 MOI (Fahimi-Vahid et al, 2002; Vogt et al,
2007; Backs et al, 2008, 2011; Zhou et al, 2008; Wuertz et al, 2010;
Carbajo-Lozoya et al, 2012; Vidal et al, 2012). The adenovirus
encoding GFP-HDAC5 was a kind gift from Eric N. Olson. Neonatal
Figure 8. Divergent pathways promoted by PGE2 synergistically activate
the transcription factor MEF2.
Schematic representation of the PGE2 triggered signal transduction pathways
converging on HDAC5 and subsequently MEF2. PGE2 activates MEF2 through EP3
receptor and the bc subunit of Gi/o proteins. One pathway implicates activation
of PKD and concomitant phosphorylation of HDAC5. The phosphorylated HDAC5
is exported from the nucleus, which results in de-repression of MEF2 and
activation of the embryonic gene programs. In addition, hand in hand activation
of Tiam1, Rac1, and PAK2 kinase occurs, which pathway also contributes to the
nuclear export of HDAC5 and is responsible for synergistic activation of MEF2.
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cardiac fibroblasts (CFs) were separated from cardiomyocytes by
pre-plating. A cell suspension equal to two neonatal rat hearts was
seeded per well of a 6-well plate. After 1 h, the supernatant was
removed, and the surface was rinsed with culture media to remove
cell debris and suspended cells. The attached cells were cultured for
2–3 days to confluence and subsequently deprived of serum 24 h
prior to stimulation. Adult mouse ventricular myocytes were
isolated as previously described (Kreusser et al, 2014). Briefly,
hearts of 6- to 12-week-old wild-type BALB/c mice were excised
after isoflurane anesthesia, which were then retrogradely perfused
and digested. The cells were plated and incubated on laminin-
coated plates for 16 h, then were serum starved for 4 h prior to
stimulation.
Pharmacological characteristics of the used inhibitors
Detailed description of the compounds and their use can be found in
Appendix Table S1.
MEF2 reporter assay
NRVMs were infected with Ad–3xMEF2-Luc to measure endogenous
MEF2 activity. 4 h after infection, the cells were serum starved for
20 h. After starvation, cells were stimulated for 24 h. Thereafter,
the cells were harvested, and luciferase activity was detected by
Promega Luciferase Assay Kit and BMG Labtech FLUOstar OPTIMA
luminometer. For standardization, the samples’ protein content was
determined by Bicinchoninic Acid Protein Assay Kit according to
manufacturer’s instruction.
Immunoblotting
After infection and/or stimulation, NRVMs and adult mouse
ventricular myocytes were washed and harvested in a solution
containing 150 mM NaCl, 50 mM Tris, pH 7.4, 1 mM EDTA, 1%
Triton X-100, 1 mM PMSF, and protease inhibitors (Complete;
Roche). To determine PAK and phospholamban phosphorylation,
NRVMs and neonatal cardiac fibroblasts were harvested in Kranias
buffer (30 mM Tris–HCl, pH 8.8, 5 mM EDTA, 30 mM NaF, 3%
SDS, 10% glycerol supplemented with protease inhibitor cocktail
and phosphatase inhibitor cocktail). Extracts from cardiac tissue
were obtained as previously described (Kreusser et al, 2014). The
lysates were denaturated, solved in Laemmli buffer, and elec-
trophoresed with SDS–PAGE, then transferred to a PVDF
membrane using wet transfer. The membrane was blocked in a 5%
skim milk/PBS solution containing 0.1% Tween-20 (PBST) or Roti-
Block (Carl Roth) solution (for detection of phosphorylated
proteins) for 30 min. The membrane was then probed with the
primary antibody overnight at 4°C. After washing three times with
PBST, the membrane was incubated with the secondary antibody
for 1 h at room temperature, followed by washing with PBST
again. The signal was detected using ECL Advance Western Blot-
ting System (GE Healthcare). The antibodies used for immunoblot-
ting were as follows: rabbit anti-phospho-HDAC5 (Ser-498;
ab47283, 1:1,000, Abcam), rabbit anti-phospho-HDAC5 (Ser-259;
produced and provided by Timothy A. McKinsey, 1:1,000), rabbit
anti-HDAC5 (#20458, 1:1,000, Cell Signaling), mouse anti-Flag M2-
peroxidase (HRP, 1:5,000, Sigma), mouse anti-GAPDH (MAB374,
1:5,000, Chemicon, Millipore), mouse anti-RhoA, (26 C4, 1:200,
Santa Cruz), mouse anti-Rac1 (610650, 1:1,000, BD Transduction),
rabbit anti-PKD/PKCl [#90039, 1:1,000, Cell Signaling (Huynh &
McKinsey, 2006)], rabbit anti-phospho-PKD/PKCl (Ser-744/748;
#2054, 1:1,000, Cell Signaling), rabbit anti-phospho-PKD/PKCl
(Ser-916; #2051, 1:1,000, Cell Signaling), rabbit anti-calsequestrin
(#PA1-913, 1:2,000, ThermoScientific), rabbit anti-PAK1/2/3
(#2604, 1:1,000, Cell Signaling, used in NRVM and CF experi-
ments), rabbit anti-PAK2 (#2615, 1:1,000, Cell Signaling, used for
mouse heart lysates), rabbit anti-phosho-PAK1/2 (Ser-199/Ser-204/
Ser-192/Ser-197; #2605, 1:1,000, Cell Signaling), rabbit anti-
phospho-PAK1/2 (Thr-423/Thr-402; #2601, 1:1,000, Cell Signaling),
rabbit anti-phospholamban (Ser-16; #A010-12, 1:5,000, Badrilla),
mouse anti-phospholamban (#A010-14, 1:5,000, Badrilla). HRP-
conjugated secondary antibodies (goat anti-rabbit and goat anti-
mouse, 1:5,000) were from Bio-Rad.
RhoGTPase activation assay
NRVMs were adenovirally infected or pretreated with the indicated
inhibitors before the RhoGTPase activation assay. The cells were
lysed in GST-Fish buffer. GTP-bound RhoA was precipitated with
the Rho-binding domain of Rhotekin, and the GTP-bound Rac1 was
precipitated with the Rac-binding domain of PAK1 coupled to
glutathione sepharose, as previously described (Vettel et al, 2012).
To determine the quantity of GTP-bound and total GTPases, immu-
noblot analysis was performed.
[3H]-Leucine incorporation assay
NRVMs were serum starved and treated 1 lCi/ml [4,5-3H]-leucine
containing media. The [3H]-incorporation was determined as previ-
ously described (Vettel et al, 2012). Briefly, after thorough washing
with ice-cold PBS, the proteins were precipitated with 10% trichlor-
oacetic acid for 4 h at 4°C. Following repeated washing with ice-
cold PBS, the pellet was dissolved with 0.1 M NaOH and 0.01% SDS
for 2 h at 37°C. Thereafter, the samples were mixed scintillation
liquid from Carl Roth GmbH. [3H]-scintillation was measured with a
Tri-Carb 2100TR Packard scintillation counter.
Immunostaining and analysis of HDAC5 cellular localization
NRVMs were grown on collagen-coated coverslips. For cell size
measurements, the cells were serum starved for 24 h and were stim-
ulated with the indicated stimuli for 48 h; the stimulation was
repeated after first 24 h. To determine the cellular localization of
HDAC5, NRVMs were transduced with GFP-HDAC5, and the
medium was changed the next day to starvation medium for 24 h.
The cells were pretreated for 2 h and stimulated for 4 h with the
indicated compounds. After stimulation, the cells were washed,
fixed in 4% paraformaldehyde, permeabilized using 0.3% Triton X-
100, and blocked in 5% goat serum-containing PBS solution. The
cells were stained with mouse anti-a-actinin (sarcomeric) primary
antibody (clone EA-53, 1:400, Sigma) and Alexa Fluor 594-conju-
gated goat anti-mouse IgG secondary antibody (#A-11005, 1:1,000,
Molecular Probes). DAPI was added in 1:10,000 dilution. Images
were taken with an Olympus BX-51 fluorescence microscope using
20× or 63× objectives. Cell size was analyzed with ImageJ software.
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Intracellular (i.e., nuclear or cytosolic) localization of GFP-HDAC5
was determined in more than 100 cells in each sample. The investi-
gator was blinded.
Induction of endotoxemia
Six- to twelve-week-old male and female BALB/c mice, harboring
a MEF2-lacZ reporter, were treated with 7 mg/kg bacterial
lipopolysaccharide (LPS) from Escherichia coli (O111:B4, Sigma-
Aldrich), as described by others (Rudyk et al, 2013). Littermates
received saline and served as a control, and the mice were randomly
allocated. Sacrificing and organ harvesting was performed after
24 h. The MEF2-lacZ reporter consists of a lacZ transgene linked to
the hsp68 basal promoter and three tandem copies of the MEF2 site
from the desmin enhancer and the MEF2-lacZ reporter mice were a
kind gift of Eric N. Olson (Naya et al, 1999; Passier et al, 2000).
Animals were kept in a 12-h/12-h light/dark cycle at 21–23°C and
fed with a standard chow diet ad libitum before experiments. All
experimental procedures were reviewed and approved by the Insti-
tutional Animal Care and Use Committee at the Regierung-
spra¨sidium Karlsruhe, Germany.
Analysis of myocardial PGE2 levels
Directly after harvest, murine hearts were frozen in liquid nitrogen
and mechanically homogenized without intermittent thawing.
Concentrations of PGE2 were determined using liquid chromatogra-
phy-tandem mass spectrometry (LC-MS/MS) as described previ-
ously (Sisignano et al, 2016). In brief, PGE2 was extracted from
homogenized tissue samples (ca. 25 mg) using liquid–liquid extrac-
tion. PGE2 was analyzed using a Synergi Hydro column
(150 × 2 mm, 4 lm, Phenomenex) coupled to a hybrid triple quad-
rupole-ion trap mass spectrometer QTRAP 5500 (Sciex, Darmstadt,
Germany) equipped with a Turbo-V-source operating in negative
ESI mode. The concentrations of the calibration standards, quality
controls, and tissue samples were evaluated by Analyst software 1.6
and MultiQuant software 3.0 (Sciex) using the internal standard
method (isotope dilution mass spectrometry). The calibration curve
was calculated by quadratic regression with 1/x2 weighting (calibra-
tion range 0.002–25 ng/sample).
RNA analysis
RNA was isolated from mouse ventricular tissue or from NRVMs
using Trizol (Invitrogen). Total RNA was digested with DNase, and
cDNA synthesis from 1,000 ng of RNA was carried out using a
SuperScript first-strand synthesis system for RT–PCR (Invitrogen).
Quantitative real-time PCR (qPCR) was performed with Universal
ProbeLibrary (Roche) by using TaqMan Universal PCR Mastermix
(Applied Biosystems) and detection on a 7500 Fast Cycler (Applied
Biosystems). Primer sequences are shown in Appendix Table S2.
In vivo assay for MEF2 activity
In vivo transcriptional activity of MEF2 was monitored using MEF2-
LacZ reporter mice, as described previously (Naya et al, 1999;
Passier et al, 2000). Briefly, the MEF2-driven b-galactosidase expres-
sion was determined by measuring the b-galactosidase activity.
After LPS or saline treatment, b-galactosidase staining was
performed on cardiac sections and whole organs, respectively, from
MEF2-lacZ reporter mice. After fixation, b-galactosidase activity was
detected by addition of the chromogenic substrate 5-bromo-4-
chloro-3-indolyl-b-D-galactoside (X-gal), which results in creation of
bright blue precipitates. Images were acquired with an Olympus
SZH zoom stereo dissection scope with an Optronics DEI-750 CCD
digital camera (using a 20× objective for histological slides); whole-
heart stainings were quantified using ImageJ software by measuring
the blue pixel intensity normalized to the total intensity.
Statistics
Results are expressed as mean  s.e.m. No statistical methods were
used to predetermine the sample size. Sample size was chosen
based on our own experience and other publications studying simi-
lar processes. Mice were randomly and blindly allocated to the
sham-treated group and the LPS-treated group. Besides that, no
randomization was used. Animals, which died in the first 24 h after
treatment, were not further examined. Besides that, no animals or
samples were excluded. To assess b-galactosidase expression and
cell size of NRVMs, the investigator was blinded during both the
image acquisition and the analysis. Analysis of HDAC5 cellular
localization was blinded as well. For statistical analysis Student’s or
Welch’s unpaired two-tailed tests, Pearson’s correlation test, one-
way or two-way ANOVA with Bonferroni post hoc tests were
performed. D’Agostino-Pearson test was used to assess normal
distribution. We considered P-values < 0.05 statistically significant.
The paper explained
Problem
The underlying mechanisms responsible for the development of
cardiac remodeling and myocardial dysfunction are still poorly under-
stood. The aim of the study was to identify and describe new signal-
ing pathways, leading to an activation of the transcription factor
myocyte enhancer factor 2 (MEF2), a central regulator of adverse
cardiac remodeling, and thereby potentially contributing to the patho-
genesis of heart failure.
Results
We found that the inflammatory mediator prostaglandin E2 (PGE2) is
a powerful activator of MEF2 in neonatal rat ventricular cardiomy-
ocytes. In accordance with that, the levels of PGE2 are increased and
MEF2 is strongly activated in a murine model of sepsis in vivo. We
provide evidence that the effects of PGE2 are transmitted by the EP3
receptor subtype and the bc subunit of the heterotrimeric Gi/o protein,
which initiate at least two parallel signaling pathways. One consists
of the guanine exchange factor Tiam1, the monomeric GTPase Rac1,
and the p21-activated kinase 2. In addition, the other pathway results
in the activation of protein kinase D, which relieves the histone
deacetylase 5-mediated repression of MEF2 activity. Inhibition of
either of the participating pathway members prevented the MEF2
activation by PGE2.
Impact
Our findings reveal an unexpected new link between inflammation
and adverse cardiac remodeling via MEF2 activation. The unmasked
upstream signaling pathway consisting of PGE2, EP3, Rac1, and PKD
may provide a number of new drug target candidates for the treat-
ment of heart failure, in particular of inflammatory cardiomyopathies.
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Expanded View for this article is available online.
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